NCT05191381 Immune Modulation by Exosomes in COVID-19
| NCT ID | NCT05191381 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Ulm |
| Condition | COVID-19 |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2021-12-22 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2021-12-22 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
Eligibility Criteria
Inclusion Criteria: * Critically ill COVID-19 patients with lung dysfunction * COVID-19 WHO severity degree \>= 4, ARDS (WHO Definition 13 March 2020) * Body weight \> 50 kg * Informed consent Exclusion Criteria: * Pregnant or breast feeding women
Contact & Investigator
Manfred Weiss, MD
PRINCIPAL INVESTIGATOR
Clinic of Anaesthesiology and Intensive Care Medicine
Frequently Asked Questions
Who can join the NCT05191381 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying COVID-19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05191381 currently recruiting?
Yes, NCT05191381 is actively recruiting participants. Contact the research team at manfred.weiss@uniklinik-ulm.de for enrollment information.
Where is the NCT05191381 trial being conducted?
This trial is being conducted at Ulm, Germany.
Who is sponsoring the NCT05191381 clinical trial?
NCT05191381 is sponsored by University of Ulm. The principal investigator is Manfred Weiss, MD at Clinic of Anaesthesiology and Intensive Care Medicine. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.